106 related articles for article (PubMed ID: 6616496)
1. Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck.
Perry DJ; Crain SM; Weltz MD; Wilson JP; Davis RK; Woolley PV; Forastiere AA; Taylor HG; Weiss RB
Cancer Treat Rep; 1983 Jan; 67(1):91-2. PubMed ID: 6616496
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of mitoguazone in patients with advanced head and neck cancer.
Thongprasert S; Bosl GJ; Geller NL; Wittes RE
Cancer Treat Rep; 1984 Oct; 68(10):1301-2. PubMed ID: 6525604
[No Abstract] [Full Text] [Related]
3. Mitoguazone in advanced squamous cell carcinoma of head and neck origin: a phase II trial of the Southeastern Cancer Study Group.
Luedke DW; Maddox W; Birch R; Velez-Garcia E; Schleuter J
Cancer Treat Rep; 1986 Apr; 70(4):529-30. PubMed ID: 3698048
[No Abstract] [Full Text] [Related]
4. [Phase II trial of mitoguazone in patients with recurrent extensive cervicofacial tumors].
Coninx P; Nasca S; Jezekova D; Roelandt H; Morel M; Legros M; Cattan A
Bull Cancer; 1985; 72(2):153-4. PubMed ID: 4005436
[No Abstract] [Full Text] [Related]
5. Phase II study of methyl-GAG in the treatment of esophageal carcinoma.
Kelsen D; Chapman R; Bains M; Heelan R; Dukeman M; Golbey R
Cancer Treat Rep; 1982 Jun; 66(6):1427-9. PubMed ID: 7083245
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
Chapman R; Kelsen D; Gralla R; Itri L; Casper E; Young C; Golbey R
Cancer Clin Trials; 1981; 4(4):389-91. PubMed ID: 6274532
[TBL] [Abstract][Full Text] [Related]
8. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.
Kish JA; Al-Sarraf M
Am J Clin Oncol; 1984 Oct; 7(5):535-7. PubMed ID: 6507374
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lung.
Scher H; Chapman R; Kelsen D; Gralla R; Wittes R
Cancer Treat Rep; 1984 Mar; 68(3):561-2. PubMed ID: 6322989
[No Abstract] [Full Text] [Related]
11. Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.
Fuks JZ; Van Echo DA; Aisner J; Mitchell EP; Woolley PV; Wiernik PH
Cancer Clin Trials; 1981; 4(4):411-4. PubMed ID: 7318123
[TBL] [Abstract][Full Text] [Related]
12. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).
Forastiere AA; Shank D; Neuberg D; Taylor SG; DeConti RC; Adams G
Cancer; 1998 Jun; 82(11):2270-4. PubMed ID: 9610709
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
[TBL] [Abstract][Full Text] [Related]
14. Mitoguazone in advanced renal carcinoma: a phase II trial of the Southwest Oncology Group.
Knight WA; Drelichman A; Fabian C; Bukowski RM
Cancer Treat Rep; 1983 Dec; 67(12):1139-40. PubMed ID: 6652631
[No Abstract] [Full Text] [Related]
15. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
Wheeler RH; Bricker LJ; Natale RB; Baker SR
Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
Magee MJ; Howard J; Bosl GJ; Wittes RE
Cancer Treat Rep; 1985 Jan; 69(1):125-6. PubMed ID: 3855384
[TBL] [Abstract][Full Text] [Related]
18. Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation.
Hart RD; Ohnuma T; Holland JF; Bruckner H
Cancer Treat Rep; 1982 Jan; 66(1):65-71. PubMed ID: 7053268
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of mitogauzone in malignant primary brain tumors.
Feun LG; Yung WK; Stewart DJ; Savaraj N; Bodey GP
Cancer Treat Rep; 1985 Mar; 69(3):329-30. PubMed ID: 3978660
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.
Yap HY; Blumenschein GR; Schell F; Bodey GP
Cancer Treat Rep; 1981; 65(5-6):465-7. PubMed ID: 7237467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
